Peanut Allergy Treatment Market Revenue Is Expected To Reach $0.74 Billion By 2029

 How Much Growth Is Anticipated In The Peanut Allergy Treatment Market Size From 2025 To 2034?

 The peanut allergy treatment market size has grown rapidly in recent years. It will grow from $0.45 billion in 2024 to $0.5 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to increased prevalence, advancements in diagnostic testing, growing public awareness and concern, development of early intervention strategies, and regulatory approvals for peanut allergy treatments.

 
 The peanut allergy treatment market size is expected to see rapid growth in the next few years. It will grow to “ $0.74 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to a continued rise in the prevalence, expansion of personalized medicine approaches, the introduction of novel immunotherapy treatments, growth in public and private investment, and expansion of telemedicine services. Major trends in the forecast period include the increased adoption of immunotherapy, advancements in biologic therapies, integration of probiotic-based treatments, technological innovations in delivery systems, personalized medicine approaches, and regulatory approvals and support.
 
 Claim Your Free Report Sample Today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=15888&type=smp
 
 Which Strategic Drivers Are Powering The Rise Of The Peanut Allergy Treatment Market?
 The investment in research and development of allergy treatments is expected to propel the growth of the peanut allergy treatment market going forward. Research and development (R&D) investment refers to the financial resources allocated by companies, organizations, or governments toward activities aimed at innovation, product development, and technological advancement. The investment in research and development for allergy treatments is crucial for advancing peanut allergy therapies. This investment fosters the creation of innovative immunotherapies and desensitization techniques, which aim to reduce allergic reactions and improve the quality of life for those affected by peanut allergies. For instance, in January 2024, the Victorian Government announced a strategic $12 million investment in Aravax, an Australia-based clinical-stage biotechnology company, to significantly advance global peanut allergy treatment. This funding is part of a broader $66 million round aimed at developing Aravax’s innovative immunotherapy, PVX108. This initiative has secured Phase 2 trial approvals from both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), underscoring its potential impact on public health worldwide. Therefore, investment in research and development of allergy treatments is driving the growth of the peanut allergy treatment market.
 
 How Do The Key Segment Classifications Define The Strategic Structure Of The Peanut Allergy Treatment Market?
 The peanut allergy treatment market covered in this report is segmented — 
 
 1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes
 2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration
 3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels
 
 Subsegments:
 1) By Antihistamines: Oral Antihistamines, Topical Antihistamines
 2) By Immunotherapies: Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), Epicutaneous Immunotherapy (EPIT)
 3) By Epinephrine: Epinephrine Auto-Injectors, Epinephrine Inhalers
 4) By Other Drug Classes: Leukotriene Receptor Antagonists, Monoclonal Antibodies, Corticosteroids
 
 What Major Trends Are Set To Shape The Peanut Allergy Treatment Market Outlook Through The Forecast Period?
 Major companies operating in the peanut allergy treatment market are focusing on the development of biologic therapies, such as anti-IgE monoclonal antibodies, to offer more targeted and effective solutions for peanut allergy management, aiming to improve patient outcomes and quality of life. Anti-IgE monoclonal antibodies are a type of therapeutic agent designed to target and neutralize immunoglobulin E (IgE) antibodies in the body. For instance, in February 2024, Novartis Pharmaceuticals Corporation, a Switzerland-based pharmaceutical company, received approval from the Food and Drug Administration (FDA) for Xolair (omalizumab). This medication is intended to reduce allergic reactions, including anaphylaxis, in patients aged 1 year and older with IgE-mediated food allergies. The approval was based on data from the NIH-sponsored Phase III OUtMATCH study, which showed significant improvement in food allergy tolerance among patients treated with Xolair compared to those who received a placebo.
 
 Which Major Industry Players Are Recognized As Strong Influencers In The Peanut Allergy Treatment Market?
 Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd., Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.
 
 Get Your In-Depth Peanut Allergy Treatment Market Report Now:
 https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report
 
 Which Regions Demonstrate The Highest Growth Momentum In The Peanut Allergy Treatment Market?
 North America was the largest region in the peanut allergy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company